Castle Biosciences, Inc. (CSTL)
NASDAQ: CSTL · Real-Time Price · USD
28.93
+0.48 (1.69%)
Nov 21, 2024, 12:37 PM EST - Market open
Castle Biosciences Stock Forecast
Stock Price Forecast
The 7 analysts with 12-month price forecasts for Castle Biosciences stock have an average target of 37.57, with a low estimate of 25 and a high estimate of 44. The average target predicts an increase of 29.87% from the current stock price of 28.93.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for CSTL stock from 7 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jun '24 | Jul '24 | Aug '24 | Sep '24 | Oct '24 | Nov '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 2 | 1 | 1 | 3 | 3 |
| Buy | 5 | 4 | 4 | 4 | 3 | 4 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 9 | 6 | 5 | 5 | 6 | 7 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Scotiabank | Scotiabank | Buy Maintains $37 → $44 | Buy | Maintains | $37 → $44 | +52.09% | Nov 6, 2024 |
| Lake Street | Lake Street | Strong Buy Maintains $34 → $40 | Strong Buy | Maintains | $34 → $40 | +38.26% | Nov 5, 2024 |
| Keybanc | Keybanc | Buy Maintains $28 → $36 | Buy | Maintains | $28 → $36 | +24.44% | Nov 5, 2024 |
| Baird | Baird | Buy Maintains $37 → $39 | Buy | Maintains | $37 → $39 | +34.81% | Nov 5, 2024 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $35 → $42 | Strong Buy | Maintains | $35 → $42 | +45.18% | Oct 29, 2024 |
Financial Forecast
Revenue This Year
327.60M
from 219.79M
Increased by 49.05%
Revenue Next Year
270.57M
from 327.60M
Decreased by -17.41%
EPS This Year
0.04
from -2.14
EPS Next Year
-2.10
from 0.04
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 346.7M | 307.8M | 348.3M | ||
| Avg | 327.6M | 270.6M | 307.8M | ||
| Low | 294.5M | 239.1M | 273.7M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 57.7% | -6.0% | 28.7% | ||
| Avg | 49.1% | -17.4% | 13.8% | ||
| Low | 34.0% | -27.0% | 1.2% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 0.46 | -1.16 | -0.42 | ||
| Avg | 0.04 | -2.10 | -1.46 | ||
| Low | -0.74 | -2.88 | -2.24 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.